VIDAZA(R) AZA-001 Study Reports Unprecedented Survival Benefit In Higher-Risk MDS Extends To AML Patients
Celgene International SÃ rl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extends to patients with acute myeloid leukemia (AML).
More: continued here
Filed under: Lymphoma / Leukemia on December 11th, 2008